Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines

European Journal of Cancer

Volumn 48, Issue 18, 2012, Pages 3488-3498

  Fan, Ping ^a   McDaniel, Russell E ^a   Kim, Helen R ^a   Clagett, Dionyssia ^a   Haddad, Bassem ^a   Craig Jordan, V ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Breast cancer cell lines; c Src; HER2; Oestrogen receptor

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; AFIMOXIFENE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; DNA CONTENT; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHATIDYLINOSITOL 3-KINASES; PROGESTERONE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS PP60(C-SRC); PYRIMIDINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84869489330     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.04.020     Document Type: Article

References (38)

1. V.C. Jordan, and A.M. Brodie Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer Steroids 72 2007 7 25 (Pubitemid 46037765)
2. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
3. S.N. Thomas, and J.S. Brugge Cellular functions regulated by Src family kinases Ann Rev Cell Dev Biol 13 1997 513 609 (Pubitemid 28034534)
4. C.W. Wong, C. McNally, E. Nickbarg, B.S. Komm, and B.J. Cheskis Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade Proc Natl Acad Sci USA 99 2002 14783 14788 (Pubitemid 35334561)
5. A.P. Belsches-Jablonski, J.S. Biscardi, and D.R. Peavy Src family kinases and HER2 interactions in human breast cancer cell growth and survival Oncogene 20 2001 1465 1475 (Pubitemid 32291197)
6. P.A. Bromann, H. Korkaya, and S.A. Courtneidge The interplay between Src family kinases and receptor tyrosine kinases Oncogene 23 2004 7957 7968 (Pubitemid 39468854)
7. M.A. Shupnik Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation Oncogene 23 2004 7979 7989 (Pubitemid 39480682)
8. S. Hiscox, L. Morgan, and T.P. Green Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells Breast Cancer Res Treat 97 2006 263 274 (Pubitemid 43945756)
9. Y. Zhao, and M.D. Planas-Silva Mislocalizaion of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity Cancer Lett 275 2009 204 212
10. P. Fan, J. Wang, R.J. Santen, and W. Yue Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells Cancer Res 67 2007 1352 1360
11. S. Zhang, W.C. Huang, and P. Li Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways Nat Med 17 2011 461 469
12. M. Talpaz, N.P. Shah, and H. Kantarjian Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2006 2531 2541 (Pubitemid 43882349)
13. G.D. Demetri, P. Lo Russo, and I.R. Macpherson Phase I dose-escalation and pharmacokinetic study of dasatinib (BMS-354825), a Src and multi-kinase inhibitor, in patients with advanced solid tumors Clin Cancer Res 15 2009 6232 6240
14. F. Huang, K. Reeves, and X. Han Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection Cancer Res 67 2007 2226 2238 (Pubitemid 46424242)
15. R.S. Finn, J. Dering, and C. Ginther Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro Breast Cancer Res Treat 105 2007 319 326 (Pubitemid 47596452)
16. R.S. Finn, C. Bengala, and N. Ibrahim Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study Clin Cancer Res 17 2011 6905 6913
17. E. Mayer, J.F. Baurain, and J.A. Sparano A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer Clin Cancer Res 17 2011 6897 6904
18. Y. Chen, N. Guggisberg, and M. Jorda Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors Clin Cancer Res 15 2009 3396 3405
19. J.J. Pink, and V.C. Jordan Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines Cancer Res 56 1996 2321 2330 (Pubitemid 26154081)
20. S.Y. Jiang, and V.C. Jordan Growth regulation of estrogen receptor negative breast cancer cells transfected with complementary DNAs for estrogen receptor J Natl Cancer Inst 84 1992 580 591
21. S.Y. Jiang, D.M. Wolf, J.M. Yingling, C. Chang, and V.C. Jordan An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol Mol Cell Endocrinol 90 1992 77 86
22. J.J. Pink, S.Y. Jiang, M. Fritsch, and V.C. Jordan An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein Cancer Res 55 1995 2583 2590
23. C.S. Murphy, J.J. Pink, and V.C. Jordan Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions Cancer Res 50 1990 7285 7292
24. H. Liu, D. Cheng, and A.K. Weichel Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells Int J Oncol 29 2006 1237 1246
25. J.S. Lewis, K. Meeke, and C. Osipo Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation J Natl Cancer Inst 97 2005 1746 1759 (Pubitemid 41782284)
26. E.J. Faivre, and C.A. Lange Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells Mol Cell Biol 27 2007 466 480 (Pubitemid 46080117)
27. D. Yu, and M.C. Hung Overexpression of ErbB2 in cancer and ErbB2-targeting strategies Oncogene 19 2000 6115 6121 (Pubitemid 32059461)
28. S.K. Muthuswamy, and W.J. Muller Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo Oncogene 11 1995 1801 1810
29. A.P. Belsches-Jablonski, J.S. Biscardi, and D.R. Peavy Src family kinases and HER2 interactions in human breast cancer cell growth and survival Oncogene 20 2001 1465 1475 (Pubitemid 32291197)
30. I. Chu, A. Arnaout, and S. Loiseau Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer J Clin Invest 117 2007 2205 2215 (Pubitemid 47219565)
31. K. Page, N. Hava, and B. Ward Detection of HER2 amplification in circulating free DNA in patients with breast cancer Br J Cancer 104 2011 1342 1348
32. D.K. Luttrell, A. Lee, and T.J. Lansing Involvement of pp 60c-src with two major signaling pathways in human breast cancer Proc Natl Acad Sci USA 91 1994 83 87
33. W. Okamoto, I. Okamoto, and T. Yoshida Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition Mol Cancer Ther 9 2010 1188 1197
34. Y. Chen, E.A. Alvarez, and D. Azzam Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo Breast Cancer Res Treat 128 2011 69 78
35. M. Tan, P. Li, and K.S. Klos ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis Cancer Res 65 2005 1858 1867 (Pubitemid 40478614)
36. L.B. Eckert, G.A. Repasky, and A.S. Ülkü Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis Cancer Res 64 2004 4585 4592 (Pubitemid 38856932)
37. M. Toulany, M. Baumann, and H.P. Rodemann Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity Mol Cancer Res 5 2007 863 872 (Pubitemid 47294813)
38. B.D. Lehmann, J.A. Bauer, and X. Chen Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2011 2750 2767